![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC52A1 |
Gene summary for SLC52A1 |
![]() |
Gene information | Species | Human | Gene symbol | SLC52A1 | Gene ID | 55065 |
Gene name | solute carrier family 52 member 1 | |
Gene Alias | GPCR42 | |
Cytomap | 17p13.2 | |
Gene Type | protein-coding | GO ID | GO:0006766 | UniProtAcc | Q9NWF4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55065 | SLC52A1 | ATC13 | Human | Thyroid | ATC | 2.12e-37 | 6.29e-01 | 0.34 |
55065 | SLC52A1 | ATC5 | Human | Thyroid | ATC | 5.57e-37 | 6.62e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603234 | Thyroid | ATC | viral process | 241/6293 | 415/18723 | 5.50e-25 | 2.04e-22 | 241 |
GO:001905835 | Thyroid | ATC | viral life cycle | 173/6293 | 317/18723 | 9.22e-15 | 5.50e-13 | 173 |
GO:004440334 | Thyroid | ATC | biological process involved in symbiotic interaction | 153/6293 | 290/18723 | 1.12e-11 | 4.12e-10 | 153 |
GO:005170134 | Thyroid | ATC | biological process involved in interaction with host | 112/6293 | 203/18723 | 1.93e-10 | 5.76e-09 | 112 |
GO:005212633 | Thyroid | ATC | movement in host environment | 94/6293 | 175/18723 | 3.20e-08 | 6.00e-07 | 94 |
GO:004440933 | Thyroid | ATC | entry into host | 76/6293 | 151/18723 | 1.54e-05 | 1.43e-04 | 76 |
GO:004671833 | Thyroid | ATC | viral entry into host cell | 72/6293 | 144/18723 | 3.38e-05 | 2.80e-04 | 72 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC52A1 | SNV | Missense_Mutation | c.1292N>A | p.Ser431Asn | p.S431N | Q9NWF4 | protein_coding | tolerated(0.47) | benign(0.057) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
SLC52A1 | SNV | Missense_Mutation | novel | c.875N>C | p.Val292Ala | p.V292A | Q9NWF4 | protein_coding | tolerated(0.08) | benign(0.009) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SLC52A1 | SNV | Missense_Mutation | c.732N>T | p.Glu244Asp | p.E244D | Q9NWF4 | protein_coding | tolerated(0.48) | probably_damaging(0.97) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC52A1 | SNV | Missense_Mutation | c.934G>A | p.Ala312Thr | p.A312T | Q9NWF4 | protein_coding | tolerated(0.26) | benign(0.028) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
SLC52A1 | SNV | Missense_Mutation | c.1121N>T | p.Gly374Val | p.G374V | Q9NWF4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DM-A1DA-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
SLC52A1 | SNV | Missense_Mutation | c.7N>T | p.Ala3Ser | p.A3S | Q9NWF4 | protein_coding | tolerated_low_confidence(0.07) | probably_damaging(0.985) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SLC52A1 | deletion | Frame_Shift_Del | c.1060delG | p.Ala354ProfsTer3 | p.A354Pfs*3 | Q9NWF4 | protein_coding | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |||
SLC52A1 | SNV | Missense_Mutation | novel | c.178N>A | p.Leu60Met | p.L60M | Q9NWF4 | protein_coding | deleterious(0.03) | probably_damaging(0.938) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC52A1 | SNV | Missense_Mutation | novel | c.1051N>A | p.Leu351Ile | p.L351I | Q9NWF4 | protein_coding | tolerated(0.67) | benign(0.014) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC52A1 | SNV | Missense_Mutation | c.1205N>A | p.Gly402Asp | p.G402D | Q9NWF4 | protein_coding | tolerated(1) | benign(0.073) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |